(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of -16.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.27%.
Sarepta Therapeutics's revenue in 2025 is $2,481,531,000.On average, 29 Wall Street analysts forecast SRPT's revenue for 2025 to be $203,830,231,668, with the lowest SRPT revenue forecast at $161,129,459,262, and the highest SRPT revenue forecast at $224,545,480,524. On average, 29 Wall Street analysts forecast SRPT's revenue for 2026 to be $158,979,763,626, with the lowest SRPT revenue forecast at $117,451,552,476, and the highest SRPT revenue forecast at $230,994,567,432.
In 2027, SRPT is forecast to generate $147,254,151,066 in revenue, with the lowest revenue forecast at $99,472,279,884 and the highest revenue forecast at $213,015,294,840.